Market Place
Sourcing Support
Apotex`s Generic Gefitinib Receives Approval in the U.S.
23 Sep 2022 //
FDA
Synthon Pharma`s Generic Gefitinib Receives Tentative Approval In US
27 Nov 2020 //
FDA
Daiichi Sankyo Announces Late-Breaking Phase 1 Dose Expansion Data
17 Sep 2020 //
BIOSPACE
Natco Pharma’s Generic Gefitinib Receives Tentative Approval In US
30 Jul 2020 //
FDA
J&J’s bispecific lung cancer antibody nabs FDA breakthrough status
11 Mar 2020 //
PMLIVE
TAGRISSO, Only 1st-line Treatment for EGFR-Mutated Non-Small cell Lung Cancer
28 Sep 2019 //
BUSINESSWIRE
Tagrisso tops rival drugs on survival in first-line lung cancer
12 Aug 2019 //
PMLIVE
Cipla`s generic Gefitinib Receives Tentative Approval in US
18 Jul 2019 //
FDA
NICE shuts down AZ`s Tagrisso—and backs Pfizer rival Vizimpro instead
09 Jul 2019 //
FIERCE PHARMA
NICE OK for life-extending Vizimpro in lung cancer
06 Jul 2019 //
PHARMATIMES
FDA Drafts Guidance on Oncology Companion Diagnostics
08 Dec 2018 //
RAPS
Mylan`s Generic Gefitinib Receives Approval in Europe
11 Oct 2018 //
EMA
China`s Pharma Boom
27 Aug 2018 //
SEEKING ALPHA
Meeting highlights from the CHMP 23-26 July 2018
31 Jul 2018 //
EMA
China answers outcry over cancer drug prices with speedy cuts
10 Jul 2018 //
FIERCE PHARMA
Pfizer’s dacomitinib bests Iressa in NSCLC OS showdown
05 Jun 2018 //
FIERCE BIOTECH
Pfizer files lung cancer drug in the EU, US
05 Apr 2018 //
PHARMA TIMES
Clock starts ticking on AZ’s first-line lung cancer filing in US
19 Dec 2017 //
PMLIVE
US priority review for AZ’ Tagrisso
18 Dec 2017 //
PHARMA TIMES
Pfizer drug delays lung cancer growth longer than Astra`s Iressa
06 Jun 2017 //
REUTERS
Chi-Med touts fruquintinib`s phase 3 safety edge in relapsed colorectal cancer
05 Jun 2017 //
FIERCE BIOTECH
Astellas Pharma To Discontinue ASP8273 Treatment Arm In Late-stage SOLAR Trial
10 May 2017 //
NASDAQ
China Widens Drug Insurance Coverage, Boosting Pharma Stocks
23 Feb 2017 //
BLOOMBERG
Generic version of AZ’s Iressa launched in China
22 Feb 2017 //
PMLIVE
Generic version of top-selling lung cancer drug hits Chinese market
20 Feb 2017 //
PHARMAFILE
Chi-Med begins phase II combo study of fruquintinib with Iressa to treat NSCLC
17 Jan 2017 //
PHARMABIZ
AstraZeneca Pill Slashes Lung Cancer Progression in Study
07 Dec 2016 //
REUTERS
GSK expects deep discount for Viread in China to boost sales
24 May 2016 //
FIERCE PHARMA
AstraZeneca keeps double-digit China growth on track in Q1
01 May 2016 //
FIERCE ASIA
Asia`s lung cancer burden
13 Apr 2016 //
BIOSPECTRUM ASIA
AZ approval for Tagrisso in Japan a big change to NSCLC treatment option in Asia
30 Mar 2016 //
FIERCE PHARMA ASIA
China NHFPC drug price pilot signals volume for cost-cuts formula
14 Mar 2016 //
FIERCE PHARMA ASIA
Boehringer’s Gilotrif to gain ground in NSCLC markets outside USA
10 Mar 2016 //
BIOSPECTRUM INDIA
Roche receives approval in Japan for the cobas® EGFR Mutation Test v2
10 Mar 2016 //
PR NEWSWIRE
BI`s Gilotrif demonstrated superiority to Iressa in reducing risk of disease
28 Jan 2016 //
PRNEWSWIRE
93 medicines recommended by CHMP in 2015
21 Dec 2015 //
PHARMATIMES
UK patients get early access to AZ`s lung cancer drug Tagrisso
09 Dec 2015 //
PM LIVE
Five medicines cleared for use by NHS Scotland
07 Dec 2015 //
PHARMATIMES
Diplomat to Dispense AstraZeneca Drug IRESSA®
10 Aug 2015 //
PR NEWS WIRE
Drugmakers eye volume growth as China cuts prices by up to 67 percent
21 May 2015 //
REUTERS
Attix Pharmaceuticals Recalls Hundreds of APIs From the U.S.
02 May 2015 //
FIERCE PHARMA MFG
Tremelimumab granted Orphan Drug Designation by US FDA for treatment of malignant mesothelioma
15 Apr 2015 //
ASTRAZENECA
